Sort   by:  
 Page size 
UnknownCanagliflozin: effects in overweight and obese subjects without diabetes mellitus.
Not available
S-EPMC4285787 | biostudies-literature
UnknownRenal safety of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in patients with type 2 diabetes mellitus.
Not available
S-EPMC5485046 | biostudies-literature
UnknownEfficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial.
Not available
S-EPMC3825495 | biostudies-literature
UnknownEfficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise.
Not available
S-EPMC3593184 | biostudies-literature
UnknownAssociation Between Circulating GDF-15 and Cardio-Renal Outcomes and Effect of Canagliflozin: Results From the CANVAS Trial.
Not available
S-EPMC9075362 | biostudies-literature
UnknownCanagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial.
Not available
S-EPMC3747923 | biostudies-literature
UnknownEffects of canagliflozin on body weight and relationship to HbA1c and blood pressure changes in patients with type 2 diabetes.
Not available
S-EPMC4800739 | biostudies-literature
UnknownEfficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial.
Not available
S-EPMC4282288 | biostudies-literature
UnknownDifferent eGFR Decline Thresholds and Renal Effects of Canagliflozin: Data from the CANVAS Program.
Not available
S-EPMC7609006 | biostudies-literature
UnknownDose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes.
Not available
S-EPMC3357223 | biostudies-literature
Sort   by:  
 Page size